Contact by medical students with the pharmaceutical industry is associated with positive attitudes about marketing, HealthDay News reports.
Medicis (NYSE:MRX) and Ipsen (Euronext:IPN) announced the U.S. Food and Drug Administration's (FDA) approval of the Biologics License Application (BLA) for DYSPORT (abobotulinumtoxinA), an acetylcholine release inhibitor and a neuromuscular blocking agent, according to GlobeNewswire.com.
Norman Levine, M.D., as evidenced in his Sep. 1, 2008, Dermatology Times Commentary (Commentary: Pharmacists, insurers limit scope of practice, prescription choices) is an articulate, caring and excellent physician, and I commend him for taking care of patients with delusions of parasitosis, a disease many of his colleagues elect to refer.
The current theory about brittle nails is that the condition is due to a decrease in water content and water retention of the nail plate, an expert says. Treatment includes educating patients and using inexpensive, over-the-counter products.
Facial hyperpigmentation: Skin of color responds well to OTC hydroquinone and non-hydroquinone products
Two products developed for treating facial hyperpigmentation in women with skin of color were compared head-to-head in a 12-week, randomized, double-blind clinical trial. Similar improvements were achieved at all follow-ups in multiple assessments among women using a hydroquinone-based product and those randomized to apply a cream containing vitamins A, C and E.
A phase 3 double-blind, placebo-controlled study shows remarkable efficacy of etanercept for treating pediatric psoriasis, bettering even those results observed in adults. The findings could help pave the way for Food and Drug Administration approval of the biologic, which could change the face of systemic treatment of psoriasis in children.
In the treatment of actinic keratoses, Peplin, a topical gel made from the sap of the Australian Euphorbia peplus, and cosmetic therapies show promise for preventing recurrences, but likely won't ever be front-line treatments. Meanwhile, the one treatment approved by the U.S. Food and Drug Administration treatment that also offers cosmetic benefits, ALA-PDT, comes with coding issues that some say make it difficult for doctors to obtain reasonable compensation.
Vapitadine (Barrier Therapeutics) is an investigational oral antihistamine that belongs to a new structural class of H1-selective, nonsedating agents. Results of a randomized, placebo-controlled clinical trial in adults with atopic dermatitis demonstrated its efficacy for relieving itch and added to an existing database showing vapitadine has an excellent safety profile.
Isotretinoin is a potent therapy for treating acne, but the associated side effects and regulatory hurdles leave dermatologists increasingly reluctant to use it.
Manufacturers of isotretinoin are awaiting more information to determine whether iPLEDGE — the mandatory federal drug registry already in place — will meet the Food and Drug Administration's new safety plan requirements.